Related Experiment Video
Updated: Jun 11, 2025
08:01
Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
Published on: November 4, 2016
12.2K
How I treat blastic plasmacytoid dendritic cell neoplasm
Mohamed A Kharfan-Dabaja1, Andrew A Lane2, Naveen Pemmaraju3
1Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL.
Blood
|October 7, 2024
Summary
Achieving complete remission is crucial for blastic plasmacytoid dendritic cell neoplasm (BPDCN) survival, especially with allogeneic hematopoietic cell transplant (allo-HCT). Total body irradiation-based myeloablative conditioning (MAC) shows survival benefits but isn't suitable for all patients.
Area of Science:
- Hematology
- Oncology
- Cellular Therapy
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) historically relied on conventional chemotherapy with limited success.
- Novel CD123-targeting therapies offer new treatment avenues for BPDCN.
- Achieving first complete remission is paramount for long-term survival in BPDCN, particularly when followed by allogeneic hematopoietic cell transplant (allo-HCT).
Purpose of the Study:
- To review current treatment strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- To evaluate the role of allogeneic hematopoietic cell transplant (allo-HCT) and conditioning regimens in BPDCN management.
- To highlight the need for personalized treatment approaches based on disease characteristics.
Main Methods:
- Review of historical and current treatment options for BPDCN.
- Analysis of data from large registries regarding conditioning regimens for allo-HCT in BPDCN.
- Discussion of reduced intensity conditioning and autologous HCT as alternative strategies.
Main Results:
- Total body irradiation-based myeloablative conditioning (MAC) regimens are associated with improved survival in allo-HCT-eligible BPDCN patients.
- MAC regimens are not feasible for older or unfit BPDCN patients, necessitating alternative approaches.
- Reduced intensity conditioning and autologous HCT are viable options for select older/unfit BPDCN patients, though supporting data are less extensive.
Conclusions:
- Optimizing BPDCN treatment requires careful consideration of patient fitness and disease status.
- Allogeneic hematopoietic cell transplant (allo-HCT) with appropriate conditioning remains a key strategy for eligible BPDCN patients.
- Further research into BPDCN's clinical, genetic, and molecular features is essential for personalized therapy development.
